ArticleFunctional & integrative genomics2026
RNA-binding protein BICC1 promotes gastric cancer progression via the PRRX1-MAPK signaling axis.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bicaudal‑C1 in Cancer: Molecular Mechanisms and Therapeutic Strategies Integrating Chinese and Western Medicine.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) poses a significant global health burden due to its elusive molecular pathogenesis. Defining key molecular drivers is essential for developing targeted therapeutics. RNA-binding proteins (RBPs) function as pivotal regulators of cancer-related mechanisms, facilitating tumor advancement and growth. Bicaudal C homolog 1 (BICC1), an understudied RBP in GC, is frequently dysregulated and strongly implicated in the progression of multiple tumor types. In this study, we observed significantly elevated BICC1 expression in GC tissues and cells. Clinical analysis identified BICC1 overexpression as an independent predictor of poor prognosis. Preclinical evidence confirmed BICC1 drives GC cell proliferation and migration both in vitro and in vivo. Mechanistically, BICC1 directly binds PRRX1 mRNA, thereby upregulating PRRX1 expression to facilitate gastric carcinogenesis through MAPK activation. Therapeutic targeting of the BICC1-PRRX1-MAPK axis represents a promising novel strategy against advanced GC.
Indexed as
Identifiers
41714520What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.